CoChat
Sign Up
Cited by 1,451

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance

Yao, Yihan, Zhou, Yunxiang, Liu, Lihong, Xu, Yanyan, Chen, Qiang, Wang, Yali, Wu, Shijie, Deng, Yongchuan, Zhang, Jianmin, Shao, Anwen·2020·Frontiers in Molecular Biosciences
DOI 10.3389/fmolb.2020.00193PMC PMC7468194
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fmolb.2020.00193

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Different types of nanoparticles (NPs) for cancer therapy. NPs applied to drug delivery systems include organic NPs, inorganic NPs and hybrid NPs. The organic NPs contain liposome-based NPs, polymer-based NPs and dendrimers. Among polymer-based NPs, polymeric NPs and polymeric micelles are common. The inorganic NPs consist of gold NPs (Au NPs), carbon nanotubes, silica NPs, magnetic NPs, and quantum dots. Hybrid NPs combine the advantages of different NPs, including lipid-polymer hybrid NPs, organic-inorganic hybrid NPs, and cell membrane-coated NPs.
FIGURE 1 Different types of nanoparticles (NPs) for cancer therapy. NPs applied to drug delivery systems include organic NPs, inorganic NPs and hybrid NPs. The organic NPs contain liposome-based NPs, polymer-based NPs and dendrimers. Among polymer-based NPs, polymeric NPs and polymeric micelles are common. The inorganic NPs consist of gold NPs (Au NPs), carbon nanotubes, silica NPs, magnetic NPs, and quantum dots. Hybrid NPs combine the advantages of different NPs, including lipid-polymer hybrid NPs, organic-inorganic hybrid NPs, and cell membrane-coated NPs.CC BY · PubMed Central
FIGURE 2 Passive and active targeting of NPs to cancer cells. Targeting of NPs enhance therapeutic efficiency and reduce systemic toxicity. Passive targeting of NPs is mainly achieved by the enhanced permeability and retention (EPR) effect, which exploits the increased vascular permeability and weakened lymphatic drainage of cancer cells and enables NPs to target cancer cells passively. Active targeting is achieved by the interaction between ligands and receptors. The receptors on cancer cells include transferrin receptors, folate receptors, glycoprotein (such as lectin), and epidermal growth factor receptor (EGFR).
FIGURE 2 Passive and active targeting of NPs to cancer cells. Targeting of NPs enhance therapeutic efficiency and reduce systemic toxicity. Passive targeting of NPs is mainly achieved by the enhanced permeability and retention (EPR) effect, which exploits the increased vascular permeability and weakened lymphatic drainage of cancer cells and enables NPs to target cancer cells passively. Active targeting is achieved by the interaction between ligands and receptors. The receptors on cancer cells include transferrin receptors, folate receptors, glycoprotein (such as lectin), and epidermal growth factor receptor (EGFR).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 176

  1. Acharya, 2011, PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect., Adv. Drug Deliv. Rev., 63, 170, 10.1016/j.addr.2010.10.008 · DOI
  2. Agarwal, 2003, Ovarian cancer: strategies for overcoming resistance to chemotherapy., Nat. Rev. Cancer, 3, 502, 10.1038/nrc1123 · DOI
  3. Alexis, 2008, HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy., ChemMedChem, 3, 1839, 10.1002/cmdc.200800122 · DOI
  4. Alimoradi, 2018, Nitric oxide-releasing nanoparticles improve doxorubicin anticancer activity., Int. J. Nanomed., 13, 7771, 10.2147/ijn.s187089 · DOI
  5. Allen, 2000, Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance., Cancer Res., 60, 5761
  6. Almeida, 2014, Amine-modified hyaluronic acid-functionalized porous silicon nanoparticles for targeting breast cancer tumors., Nanoscale, 6, 10377, 10.1039/c4nr02187h · DOI
  7. Amreddy, 2018, Recent advances in nanoparticle-based cancer drug and gene delivery., Adv. Cancer Res., 137, 115, 10.1016/bs.acr.2017.11.003 · DOI
  8. Amreddy, 2015, Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy., Int. J. Nanomed., 10, 6773, 10.2147/ijn.s93237 · DOI
  9. Apte, 2019, VEGF in signaling and disease: beyond discovery and development., Cell, 176, 1248, 10.1016/j.cell.2019.01.021 · DOI · Paper page
  10. Bahrami, 2017, Nanoparticles and targeted drug delivery in cancer therapy., Immunol. Lett., 190, 64, 10.1016/j.imlet.2017.07.015 · DOI
  11. Bai, 2013, Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer., Biomaterials, 34, 6163, 10.1016/j.biomaterials.2013.04.062 · DOI
  12. Balasubramanian, 2014, Curcumin and 5-fluorouracil-loaded, folate- and transferrin-decorated polymeric magnetic nanoformulation: a synergistic cancer therapeutic approach, accelerated by magnetic hyperthermia., Int. J. Nanomed., 9, 437, 10.2147/ijn.s49882 · DOI
  13. Basoglu, 2018, Magnetic nanoparticle-mediated gene therapy to induce Fas apoptosis pathway in breast cancer., Cancer Gene Ther, 25, 141, 10.1038/s41417-018-0017-2 · DOI
  14. Bauleth-Ramos, 2017, Nutlin-3a and cytokine co-loaded spermine-modified acetalated dextran nanoparticles for cancer chemo-immunotherapy., Adv. Funct. Mater., 27, 10.1002/adfm.201703303 · DOI
  15. Bertrand, 2014, Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology., Adv. Drug Deliv. Rev., 66, 2, 10.1016/j.addr.2013.11.009 · DOI
  16. Braunová, 2017, Tumor-targeted micelle-forming block copolymers for overcoming of multidrug resistance., J. Control Release, 245, 41, 10.1016/j.jconrel.2016.11.020 · DOI
  17. Carita, 2018, Recent advances and perspectives in liposomes for cutaneous drug delivery., Curr. Med. Chem., 25, 606, 10.2174/0929867324666171009120154 · DOI
  18. Carmeliet, 2000, Angiogenesis in cancer and other diseases., Nature, 407, 249, 10.1038/35025220 · DOI · Paper page
  19. Chen, 2009, Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells., Small, 5, 2673, 10.1002/smll.200900621 · DOI
  20. Chen, 2017, Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis., Int. J. Pharm., 529, 102, 10.1016/j.ijpharm.2017.06.071 · DOI
  21. Chen, 2015, In vivo delivery of miRNAs for cancer therapy: challenges and strategies., Adv. Drug Deliv. Rev., 81, 128, 10.1016/j.addr.2014.05.009 · DOI
  22. Chen, 2010, Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy., Mol. Ther., 18, 1650, 10.1038/mt.2010.136 · DOI
  23. Cheng, 2019, Supramolecular Nanomachines as Stimuli-Responsive Gatekeepers on Mesoporous Silica Nanoparticles for Antibiotic and Cancer Drug Delivery., Theranostics, 9, 3341, 10.7150/thno.34576 · DOI
  24. Cheng, 2018, Overcoming STC2 mediated drug resistance through drug and gene co-delivery by PHB-PDMAEMA cationic polyester in liver cancer cells., Mater. Sci. Eng. C Mater. Biol. Appl., 83, 210, 10.1016/j.msec.2017.08.075 · DOI · Paper page
  25. Cheng, 2013, Surface functionalized gold nanoparticles for drug delivery., J. Biomed. Nanotechnol., 9, 1362, 10.1166/jbn.2013.1536 · DOI
  26. Cheow, 2011, Factors affecting drug encapsulation and stability of lipid-polymer hybrid nanoparticles., Colloids Surf. B Biointerfaces, 85, 214, 10.1016/j.colsurfb.2011.02.033 · DOI
  27. Chintamani, Singh, 2005, Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer–a prospective clinical study., World J. Surg. Oncol., 3, 10.1186/1477-7819-3-61 · DOI
  28. Choi, 2019, Binary Targeting of siRNA to Hematologic Cancer Cells In Vivo using Layer-by-Layer Nanoparticles., Adv. Funct. Mater., 29, 10.1002/adfm.201900018 · DOI
  29. Choi, 2008, Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells., Eur. J. Pharm. Biopharm., 68, 545, 10.1016/j.ejpb.2007.07.011 · DOI
  30. Cirillo, 2019, Combining Carbon Nanotubes and Chitosan for the Vectorization of Methotrexate to Lung Cancer Cells., Materials, 12, 10.3390/ma12182889 · DOI
  31. Colapicchioni, 2015, Killing cancer cells using nanotechnology: novel poly(I:C) loaded liposome-silica hybrid nanoparticles., J. Mater. Chem. B, 3, 7408, 10.1039/c5tb01383f · DOI
  32. Cortes, 2010, Nanoparticle albumin-bound (nab (TM))-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer., EJC Suppl., 8, 1, 10.1016/s1359-6349(10)70002-1 · DOI
  33. Cui, 2017, Enhanced intracellular delivery and controlled drug release of magnetic PLGA nanoparticles modified with transferrin., Acta Pharmacol. Sin., 38, 943, 10.1038/aps.2017.45 · DOI
  34. Cun, 2019, Tumor-Associated Fibroblast-Targeted Regulation and Deep Tumor Delivery of Chemotherapeutic Drugs with a Multifunctional Size-Switchable Nanoparticle., ACS Appl. Mater. Interfaces, 11, 39545, 10.1021/acsami.9b13957 · DOI
  35. Cuvier, 1992, Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance., Biochem. Pharmacol., 44, 509, 10.1016/0006-2952(92)90443-m · DOI
  36. Dadwal, 2018, Nanoparticles as carriers for drug delivery in cancer., Artif. Cells Nanomed. Biotechnol., 46, 295, 10.1080/21691401.2018.1457039 · DOI
  37. Danhier, 2010, To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery., J. Control Release, 148, 135, 10.1016/j.jconrel.2010.08.027 · DOI
  38. Davis, 2010, Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles., Nature, 464, 1067, 10.1038/nature08956 · DOI
  39. Decuzzi, 2009, Intravascular delivery of particulate systems: does geometry really matter?, Pharm. Res., 26, 235, 10.1007/s11095-008-9697-x · DOI
  40. Dehaini, 2017, Erythrocyte-platelet hybrid membrane coating for enhanced nanoparticle functionalization., Adv. Mater., 29, 10.1002/adma.201606209 · DOI
  41. Desgrosellier, 2010, Integrins in cancer: biological implications and therapeutic opportunities., Nat. Rev. Cancer, 10, 9, 10.1038/nrc2748 · DOI
  42. Devalapally, 2007, Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer., Int. J. Cancer, 121, 1830, 10.1002/ijc.22886 · DOI
  43. Dienst, 2005, Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins., J. Natl. Cancer Inst., 97, 733, 10.1093/jnci/dji130 · DOI
  44. Eloy, 2016, Co-loaded paclitaxel/rapamycin liposomes: development, characterization and in vitro and in vivo evaluation for breast cancer therapy., Colloids Surf. B Biointerfaces, 141, 74, 10.1016/j.colsurfb.2016.01.032 · DOI
  45. Fan, 2010, Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance., Biomaterials, 31, 5634, 10.1016/j.biomaterials.2010.03.066 · DOI
  46. Fang, 2018, Cell Membrane Coating Nanotechnology., Adv. Mater., 30, 10.1002/adma.201706759 · DOI · Paper page
  47. Farokhzad, 2009, Impact of nanotechnology on drug delivery., ACS Nano, 3, 16, 10.1021/nn900002m · DOI
  48. Fontana, Delivery of therapeutics with nanoparticles: what’s new in cancer immunotherapy?, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 9, 10.1002/wnan.1421 · DOI
  49. Fontana, Multistaged Nanovaccines Based on Porous Silicon@Acetalated Dextran@Cancer Cell Membrane for Cancer Immunotherapy., Adv. Mater., 29, 10.1002/adma.201603239 · DOI
  50. Gao, 2019, Biodegradable, pH-Sensitive Hollow Mesoporous Organosilica Nanoparticle (HMON) with Controlled Release of Pirfenidone and Ultrasound-Target-Microbubble-Destruction (UTMD) for Pancreatic Cancer Treatment., Theranostics, 9, 6002, 10.7150/thno.36135 · DOI
  51. Gao, 2017, iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability., Int. J. Nanomed., 12, 4147, 10.2147/ijn.s134148 · DOI
  52. Geisberg, 2010, Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage., Curr. Hypertens. Rep., 12, 404, 10.1007/s11906-010-0146-y · DOI
  53. Guo, 2015, Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma., ACS Nano, 9, 6918, 10.1021/acsnano.5b01042 · DOI
  54. Hajizadeh, 2020, Silencing of HIF-1α/CD73 axis by siRNA-loaded TAT-chitosan-spion nanoparticles robustly blocks cancer cell progression., Eur. J. Pharmacol., 882, 10.1016/j.ejphar.2020.173235 · DOI
  55. Han, 2020, Preparation, Characterization, and Pharmacokinetic Study of a Novel Long-Acting Targeted Paclitaxel Liposome with Antitumor Activity., Int. J. Nanomed., 15, 553, 10.2147/ijn.s228715 · DOI
  56. Han, 2007, Functionalized gold nanoparticles for drug delivery., Nanomedicine, 2, 113, 10.2217/17435889.2.1.113 · DOI
  57. He, 2019, Cancer Cell Membrane Decorated Silica Nanoparticle Loaded with miR495 and Doxorubicin to Overcome Drug Resistance for Effective Lung Cancer Therapy., Nanoscale Res. Lett., 14, 10.1186/s11671-019-3143-3 · DOI
  58. Hood, 2002, Tumor regression by targeted gene delivery to the neovasculature., Science, 296, 2404, 10.1126/science.1070200 · DOI
  59. Hoopes, 2017, Hypo-fractionated radiation, magnetic nanoparticle hyperthermia and a viral immunotherapy treatment of spontaneous canine cancer., Proc. SPIE Int. Soc. Opt. Eng., 10066, 10.1117/12.2256213 · DOI
  60. Hrkach, 2012, Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile., Sci. Transl. Med., 4, 10.1126/scitranslmed.3003651 · DOI
  61. Hu, 2010, Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells., Mol. Pharm., 7, 914, 10.1021/mp900316a · DOI
  62. Hu, 2015, Engineering the lipid layer of lipid-PLGA hybrid nanoparticles for enhanced in vitro cellular uptake and improved stability., Acta Biomater., 28, 149, 10.1016/j.actbio.2015.09.032 · DOI
  63. Hua, 2013, The use of lipid-based nanocarriers for targeted pain therapies., Front. Pharmacol., 4, 10.3389/fphar.2013.00143 · DOI
  64. Iwase, 2012, Preparation and in vivo evaluation of liposomal everolimus for lung carcinoma and thyroid carcinoma., Biol. Pharm. Bull., 35, 975, 10.1248/bpb.35.975 · DOI
  65. Jain, 1994, Barriers to drug delivery in solid tumors., Sci. Am., 271, 58, 10.1038/scientificamerican0794-58 · DOI
  66. Jiang, 2019, Erythrocyte-cancer hybrid membrane-camouflaged melanin nanoparticles for enhancing photothermal therapy efficacy in tumors., Biomaterials, 192, 292, 10.1016/j.biomaterials.2018.11.021 · DOI
  67. Jiang, 2016, Progress and perspective of inorganic nanoparticle-based siRNA delivery systems., Expert. Opin. Drug Deliv., 13, 547, 10.1517/17425247.2016.1134486 · DOI
  68. Jing, 2019, Role of hypoxia in cancer therapy by regulating the tumor microenvironment., Mol. Cancer, 18, 10.1186/s12943-019-1089-9 · DOI · Paper page
  69. Kalyane, 2019, Employment of enhanced permeability and retention effect (EPR): nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer., Mater. Sci. Eng. C Mater. Biol. Appl., 98, 1252, 10.1016/j.msec.2019.01.066 · DOI
  70. Kamaly, 2012, Targeted polymeric therapeutic nanoparticles: design, development and clinical translation., Chem. Soc. Rev., 41, 2971, 10.1039/c2cs15344k · DOI
  71. Khiste, 2020, Ceramide-rubusoside nanomicelles, a potential therapeutic approach to target cancers carrying p53 missense mutations., Mol. Cancer Ther., 19, 564, 10.1158/1535-7163.mct-19-0366 · DOI
  72. Kipp, 2004, The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs., Int. J. Pharm., 284, 109, 10.1016/j.ijpharm.2004.07.019 · DOI
  73. Kong, 2015, Inhibition of Multidrug Resistance of Cancer Cells by Co-Delivery of DNA Nanostructures and Drugs Using Porous Silicon Nanoparticles@Giant Liposomes., Adv. Funct. Mater., 25, 3330, 10.1002/adfm.201500594 · DOI
  74. Kundu, 2019, pH-responsive and targeted delivery of curcumin via phenylboronic acid-functionalized ZnO nanoparticles for breast cancer therapy., J. Adv. Res., 18, 161, 10.1016/j.jare.2019.02.036 · DOI
  75. Legge, 2019, Targeted magnetic nanoparticle hyperthermia for the treatment of oral cancer., J. Oral Pathol. Med., 48, 803, 10.1111/jop.12921 · DOI
  76. Lei, 2019, Polydopamine-coated mesoporous silica nanoparticles for multi-responsive drug delivery and combined chemo-photothermal therapy., Mater. Sci. Eng. C Mater. Biol. Appl., 105, 10.1016/j.msec.2019.110103 · DOI
  77. Lemière, 2015, Cell-sized liposomes that mimic cell motility and the cell cortex., Methods Cell Biol., 128, 271, 10.1016/bs.mcb.2015.01.013 · DOI
  78. Li, 2018, Tailoring porous silicon for biomedical applications: from drug delivery to cancer immunotherapy., Adv. Mater., 30, 10.1002/adma.201703740 · DOI
  79. Li, 2016, Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies., Drug Resist. Updat., 27, 14, 10.1016/j.drup.2016.05.001 · DOI · Paper page
  80. Li, 2019, In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis., Biomaterials, 188, 160, 10.1016/j.biomaterials.2018.10.019 · DOI
  81. Lia, 2009, Selective matrix metalloproteinase inhibitors for cancer., Curr. Med. Chem., 16, 3805, 10.2174/092986709789178037 · DOI
  82. Lim, 2018, Recent advances in pH-sensitive polymeric nanoparticles for smart drug delivery in cancer therapy., Curr. Drug Targets, 19, 300, 10.2174/1389450117666160602202339 · DOI
  83. Litman, 2000, The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter. MXR (ABCG2)., J. Cell Sci., 113, 2011, 10.1242/jcs.113.11.2011 · DOI
  84. Liu, 2019, Cancer cell membrane-cloaked mesoporous silica nanoparticles with a pH-sensitive gatekeeper for cancer treatment., Colloids Surf. B Biointerfaces, 175, 477, 10.1016/j.colsurfb.2018.12.038 · DOI
  85. Liu, 2015, Dihydroartemisinin and transferrin dual-dressed nano-graphene oxide for a pH-triggered chemotherapy., Biomaterials, 62, 35, 10.1016/j.biomaterials.2015.05.036 · DOI
  86. Long, 2018, Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model., Nanomedicine, 14, 789, 10.1016/j.nano.2017.12.014 · DOI
  87. Low, 2009, Folate-targeted therapeutic and imaging agents for cancer., Curr. Opin. Chem. Biol., 13, 256, 10.1016/j.cbpa.2009.03.022 · DOI
  88. Luan, 2018, A tumor vascular-targeted interlocking trimodal nanosystem that induces and exploits hypoxia., Adv. Sci., 5, 10.1002/advs.201800034 · DOI
  89. Luo, 2013, The toxicity and pharmacokinetics of carbon nanotubes as an effective drug carrier., Curr. Drug Metab., 14, 879, 10.2174/138920021131400110 · DOI
  90. Madani, 2011, A new era of cancer treatment: carbon nanotubes as drug delivery tools., Int. J. Nanomed., 6, 2963, 10.2147/ijn.s16923 · DOI
  91. Maeda, 2001, The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting., Adv. Enzyme Regul., 41, 189, 10.1016/s0065-2571(00)00013-3 · DOI · Paper page
  92. Mandriota, 2019, Design and application of cisplatin-loaded magnetic nanoparticle clusters for smart chemotherapy., ACS Appl. Mater. Interfaces, 11, 1864, 10.1021/acsami.8b18717 · DOI
  93. Mansour, 2003, A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2., Cancer Res., 63, 4062
  94. Meng, 2015, Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice., ACS Nano, 9, 3540, 10.1021/acsnano.5b00510 · DOI
  95. Meng, 2016, Combination Therapy using Co-encapsulated Resveratrol and Paclitaxel in Liposomes for Drug Resistance Reversal in Breast Cancer Cells in vivo., Sci. Rep., 6, 10.1038/srep22390 · DOI
  96. Minko, 2004, Drug targeting to the colon with lectins and neoglycoconjugates., Adv. Drug Deliv. Rev., 56, 491, 10.1016/j.addr.2003.10.017 · DOI
  97. Misra, 2010, Cancer nanotechnology: application of nanotechnology in cancer therapy., Drug Discov. Today, 15, 842, 10.1016/j.drudis.2010.08.006 · DOI
  98. Misra, 2011, Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells., Mol. Pharm., 8, 852, 10.1021/mp100455h · DOI
  99. Mottaghitalab, 2019, New insights into designing hybrid nanoparticles for lung cancer: diagnosis and treatment., J. Control Release, 295, 250, 10.1016/j.jconrel.2019.01.009 · DOI
  100. Murakami, 2011, Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting., Sci. Transl. Med., 3, 10.1126/scitranslmed.3001385 · DOI
  101. Muralidharan, 2016, Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration., J. Nanobiotechnol., 14, 10.1186/s12951-016-0201-1 · DOI
  102. Najafi-Hajivar, 2016, Overview on experimental models of interactions between nanoparticles and the immune system., Biomed. Pharmacother., 83, 1365, 10.1016/j.biopha.2016.08.060 · DOI
  103. Nanjwade, 2009, Dendrimers: emerging polymers for drug-delivery systems., Eur. J. Pharm. Sci., 38, 185, 10.1016/j.ejps.2009.07.008 · DOI
  104. Navarro, 2012, P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells., Nanomedicine, 7, 65, 10.2217/nnm.11.93 · DOI
  105. Nicholson, 2001, EGFR and cancer prognosis., Eur. J. Cancer, 37, S9, 10.1016/s0959-8049(01)00231-3 · DOI
  106. Nisato, 2003, alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro., Angiogenesis, 6, 105, 10.1023/B:AGEN.0000011801.98187.f2 · DOI
  107. Obaid, 2015, Cancer targeting with biomolecules: a comparative study of photodynamic therapy efficacy using antibody or lectin conjugated phthalocyanine-PEG gold nanoparticles., Photochem. Photobiol. Sci., 14, 737, 10.1039/c4pp00312h · DOI
  108. O’Brien, 2004, Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer., Ann. Oncol., 15, 440, 10.1093/annonc/mdh097 · DOI
  109. Orleth, 2016, Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy., J. Drug Target, 24, 80, 10.3109/1061186x.2015.1056189 · DOI
  110. Palazzolo, 2018, The clinical translation of organic nanomaterials for cancer therapy: a focus on polymeric nanoparticles, micelles, liposomes and exosomes., Curr. Med. Chem., 25, 4224, 10.2174/0929867324666170830113755 · DOI
  111. Pan, 2013, Programmable nanoparticle functionalization for in vivo targeting., FASEB J., 27, 255, 10.1096/fj.12-218081 · DOI
  112. Park, 2009, Multifunctional nanoparticles for combined doxorubicin and photothermal treatments., ACS Nano, 3, 2919, 10.1021/nn900215k · DOI
  113. Parodi, 2013, Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions., Nat. Nanotechnol., 8, 61, 10.1038/nnano.2012.212 · DOI
  114. Patil, 2010, The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance., Biomaterials, 31, 358, 10.1016/j.biomaterials.2009.09.048 · DOI
  115. Paulis, 2013, Dendritic cell-based nanovaccines for cancer immunotherapy., Curr. Opin. Immunol., 25, 389, 10.1016/j.coi.2013.03.001 · DOI
  116. Pelicano, 2006, Glycolysis inhibition for anticancer treatment., Oncogene, 25, 4633, 10.1038/sj.onc.1209597 · DOI
  117. Perica, 2014, Nanoscale artificial antigen presenting cells for T cell immunotherapy., Nanomedicine, 10, 119, 10.1016/j.nano.2013.06.015 · DOI
  118. Perrault, 2009, Mediating tumor targeting efficiency of nanoparticles through design., Nano Lett., 9, 1909, 10.1021/nl900031y · DOI
  119. Prabha, 2004, Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells., Mol. Pharm., 1, 211, 10.1021/mp049970 · DOI
  120. Qin, 2018, Multifunctional micelle delivery system for overcoming multidrug resistance of doxorubicin., J. Drug Target, 26, 289, 10.1080/1061186x.2017.1379525 · DOI
  121. Reddy, 2011, Combined treatment targeting HIF-1α and Stat3 is a potent strategy for prostate cancer therapy., Prostate, 71, 1796, 10.1002/pros.21397 · DOI
  122. Rey, 2017, Targeting Hypoxia-inducible factors for antiangiogenic cancer therapy., Trends Cancer, 3, 529, 10.1016/j.trecan.2017.05.002 · DOI
  123. Riley, 2017, Gold nanoparticle-mediated photothermal therapy: applications and opportunities for multimodal cancer treatment., Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 9, 10.1002/wnan.1449 · DOI
  124. Ruoslahti, 2002, Specialization of tumour vasculature., Nat. Rev. Cancer, 2, 83, 10.1038/nrc724 · DOI
  125. Saad, 2008, Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer., Nanomedicine, 3, 761, 10.2217/17435889.3.6.761 · DOI
  126. Samadian, 2016, Folate-conjugated gold nanoparticle as a new nanoplatform for targeted cancer therapy., J. Cancer Res. Clin. Oncol., 142, 2217, 10.1007/s00432-016-2179-3 · DOI
  127. Saneja, 2019, Gemcitabine and betulinic acid co-encapsulated PLGA-PEG polymer nanoparticles for improved efficacy of cancer chemotherapy., Mater. Sci. Eng. C Mater. Biol. Appl., 98, 764, 10.1016/j.msec.2019.01.026 · DOI
  128. Santi, 2017, Rational Design of a Transferrin-Binding Peptide Sequence Tailored to Targeted Nanoparticle Internalization., Bioconjug. Chem., 28, 471, 10.1021/acs.bioconjchem.6b00611 · DOI
  129. Satsangi, 2015, Synthesis of a novel, sequentially active-targeted drug delivery nanoplatform for breast cancer therapy., Biomaterials, 59, 88, 10.1016/j.biomaterials.2015.03.039 · DOI
  130. Schneider, 1998, ATP-binding-cassette (ABC) transport systems: functional and structural aspects of the ATP-hydrolyzing subunits/domains., FEMS Microbiol. Rev., 22, 1, 10.1111/j.1574-6976.1998.tb00358.x · DOI
  131. Semenza, 2007, Evaluation of HIF-1 inhibitors as anticancer agents., Drug Discov. Today, 12, 853, 10.1016/j.drudis.2007.08.006 · DOI · Paper page
  132. Shao, 2015, Nanoparticle-based immunotherapy for cancer., ACS Nano, 9, 16, 10.1021/nn5062029 · DOI
  133. Sherje, 2018, Dendrimers: a versatile nanocarrier for drug delivery and targeting., Int. J. Pharm., 548, 707, 10.1016/j.ijpharm.2018.07.030 · DOI
  134. Shi, 2011, Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation., ACC Chem. Res., 44, 1123, 10.1021/ar200054n · DOI
  135. Sigismund, 2018, Emerging functions of the EGFR in cancer., Mol. Oncol., 12, 3, 10.1002/1878-0261.12155 · DOI
  136. Singh, 2018, Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer., Cancer Lett., 427, 49, 10.1016/j.canlet.2018.04.017 · DOI
  137. Soe, 2019, Transferrin-conjugated polymeric nanoparticle for receptor-mediated delivery of doxorubicin in Doxorubicin-resistant breast cancer cells., Pharmaceutics, 11, 10.3390/pharmaceutics11020063 · DOI
  138. Soma, 2000, Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles., Biomaterials, 21, 1, 10.1016/s0142-9612(99)00125-8 · DOI
  139. Su, 2013, Lipid-polymer nanoparticles encapsulating doxorubicin and 2′-deoxy-5-azacytidine enhance the sensitivity of cancer cells to chemical therapeutics., Mol. Pharm., 10, 1901, 10.1021/mp300675c · DOI
  140. Sui, 2011, COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer., Carcinogenesis, 32, 667, 10.1093/carcin/bgr016 · DOI
  141. Susa, 2009, Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma., BMC Cancer, 9, 10.1186/1471-2407-9-399 · DOI
  142. Sykes, 2014, Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency., ACS Nano, 8, 5696, 10.1021/nn500299p · DOI
  143. Tang, 2020, Design, preparation and evaluation of different branched biotin modified liposomes for targeting breast cancer., Eur. J. Med. Chem., 193, 10.1016/j.ejmech.2020.112204 · DOI
  144. Tang, 2020, The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation DNA repair pathway., Nanoscale Res. Lett., 15, 10.1186/s11671-020-3289-z · DOI
  145. Vadde, 2017, Role of hypoxia-inducible factors (HIF) in the maintenance of stemness and malignancy of colorectal cancer., Crit. Rev. Oncol. Hematol., 113, 22, 10.1016/j.critrevonc.2017.02.025 · DOI
  146. van Vlerken, 2010, Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems., AAPS J., 12, 171, 10.1208/s12248-010-9174-4 · DOI
  147. Venturoli, 2005, Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability., Am. J. Physiol. Renal. Physiol., 288, F605, 10.1152/ajprenal.00171.2004 · DOI
  148. Viktorsson, 2005, Apoptotic pathways and therapy resistance in human malignancies., Adv. Cancer Res., 94, 143, 10.1016/s0065-230x(05)94004-9 · DOI
  149. Wang, Erythrocyte-Cancer Hybrid Membrane Camouflaged Hollow Copper Sulfide Nanoparticles for Prolonged Circulation Life and Homotypic-Targeting Photothermal/Chemotherapy of Melanoma., ACS Nano, 12, 5241, 10.1021/acsnano.7b08355 · DOI
  150. Wang, Overcoming Ovarian Cancer Drug Resistance with a Cold Responsive Nanomaterial., ACS Cent. Sci., 4, 567, 10.1021/acscentsci.8b00050 · DOI
  151. Wang, Targeted production of reactive oxygen species in mitochondria to overcome cancer drug resistance., Nat. Commun., 9, 10.1038/s41467-018-02915-8 · DOI
  152. Wang, 2020, Tumor- and mitochondria-targeted nanoparticles eradicate drug resistant lung cancer through mitochondrial pathway of apoptosis., J. Nanobiotechnol., 18, 10.1186/s12951-019-0562-3 · DOI
  153. Wang, 2017, Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer., Sci. Rep., 7, 10.1038/s41598-017-06142-x · DOI
  154. Wang, 2017, Sensitivity to antitubulin chemotherapeutics is potentiated by a photoactivable nanoliposome., Biomaterials, 141, 50, 10.1016/j.biomaterials.2017.06.034 · DOI
  155. Wang, 2006, Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer., Nat. Mater., 5, 791, 10.1038/nmat1737 · DOI
  156. Wong, 2011, Multistage nanoparticle delivery system for deep penetration into tumor tissue., Proc. Natl. Acad. Sci. U.S.A., 108, 2426, 10.1073/pnas.1018382108 · DOI
  157. Xia, 2005, Effects of hypoxia on expression of P-gp and mutltidrug resistance protein in human lung adenocarcinoma A549 cell line., J. Huazhong Univ. Sci. Technolog. Med. Sci., 25, 279, 10.1007/bf02828142 · DOI
  158. Xiao, 2018, A drug-delivering-drug strategy for combined treatment of metastatic breast cancer., Nanomedicine, 14, 2678, 10.1016/j.nano.2018.06.012 · DOI
  159. Xu, 2019, Mesoporous silica nanoparticles for protein protection and delivery., Front. Chem., 7, 10.3389/fchem.2019.00290 · DOI
  160. Yang, 2014, Evading immune cell uptake and clearance requires PEG grafting at densities substantially exceeding the minimum for brush conformation., Mol. Pharm., 11, 1250, 10.1021/mp400703d · DOI
  161. Yang, 2018, Cancer cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination., ACS Nano, 12, 5121, 10.1021/acsnano.7b09041 · DOI
  162. Yari, 2019, Surface modification of liposomes by a lipopolymer targeting prostate specific membrane antigen for theranostic delivery in prostate cancer., Materials, 12, 10.3390/ma12050756 · DOI
  163. Yoon, 2018, Engineering nanoparticle strategies for effective cancer immunotherapy., Biomaterials, 178, 597, 10.1016/j.biomaterials.2018.03.036 · DOI
  164. Yu, 2018, A degradable triple temperature-, pH-, and redox-responsive drug system for cancer chemotherapy., J. Biomed. Mater. Res. A, 106, 3203, 10.1002/jbm.a.36515 · DOI
  165. Zang, 2017, Nanoparticles for tumor immunotherapy., Eur. J. Pharm. Biopharm., 115, 243, 10.1016/j.ejpb.2017.03.013 · DOI
  166. Zhang, 2017, Receptor-mediated surface charge inversion platform based on porous silicon nanoparticles for efficient cancer cell recognition and combination therapy., ACS Appl. Mater. Interfaces, 9, 10034, 10.1021/acsami.7b02196 · DOI
  167. Zhang, 2017, Design of nanocarriers for nanoscale drug delivery to enhance cancer treatment using hybrid polymer and lipid building blocks., Nanoscale, 9, 1334, 10.1039/c6nr08486a · DOI
  168. Zhang, 2019, Nanoparticle therapy for prostate cancer: overview and perspectives., Curr. Top. Med. Chem., 19, 57, 10.2174/1568026619666190125145836 · DOI
  169. Zhang, 2019, pH and redox dual-responsive nanoparticles based on disulfide-containing poly(β-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer., J. Nanobiotechnol., 17, 10.1186/s12951-019-0540-9 · DOI
  170. Zhang, 2018, Hypoxia-inducible factor-1α/interleukin-1β signaling enhances hepatoma epithelial-mesenchymal transition through macrophages in a hypoxic-inflammatory microenvironment., Hepatology, 67, 1872, 10.1002/hep.29681 · DOI · Paper page
  171. Zhang, 2008, Self-assembled lipid–polymer hybrid nanoparticles: a robust drug delivery platform., ACS Nano, 2, 1696, 10.1021/nn800275r · DOI
  172. Zhao, 2019, Co-Delivery of Curcumin and Paclitaxel by “Core-Shell” targeting amphiphilic copolymer to reverse resistance in the treatment of ovarian cancer., Int. J. Nanomed., 14, 9453, 10.2147/ijn.s224579 · DOI
  173. Zhao, 2015, Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer., Biomaterials, 46, 13, 10.1016/j.biomaterials.2014.12.028 · DOI
  174. Zhao, 2016, Doxorubicin and resveratrol co-delivery nanoparticle to overcome doxorubicin resistance., Sci. Rep., 6, 10.1038/srep35267 · DOI
  175. Zhou, 2018, Stimuli-responsive polymeric micelles for drug delivery and cancer therapy., Int. J. Nanomed., 13, 2921, 10.2147/ijn.s158696 · DOI
  176. Zylberberg, 2016, Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape., Drug Deliv., 23, 3319, 10.1080/10717544.2016.1177136 · DOI

Cited by

Sorted by citations

See all 1,451

Metadata

Authors
Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A.
Venue
Frontiers in Molecular Biosciences
Publisher
Frontiers Media SA
Published
2020-08-20
Volume
7
ISSN
2296-889X
DOI
10.3389/fmolb.2020.00193
PMC
PMC7468194
Cited by
1,451
References
4
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
  • National Natural Science Foundation of China
  • National Basic Research Program of China

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review